Table 3.
Comparison of baseline demographics and clinical characteristics between patients with and without recurrence
| Comparison | Univariate Cox Regression | |||||
|---|---|---|---|---|---|---|
|
No-Recurrence (n = 76) |
Recurrence (n = 68) |
p value | HR | 95%Cl | P value | |
| Demographic Data | ||||||
| Age, years | 60 ± 11 | 61 ± 9 | 0.63 | 0.99 | 0.98–1.02 | 0.69 |
| Men, n (%) | 63 (83) | 48(71) | 0.06 | 1.12 | 0.66–1.90 | 0.67 |
| Body mass index, kg/m2 | 30 ± 5 | 31 ± 6 | 0.04 | 1.04 | 1.00–1.08 | 0.05 |
| Paroxysmal AF, (%) | 48(63) | 30(44) | 0.02 | 0.62 | 0.38–1.00 | 0.05 |
| AF duration, years | 6.1 ± 6.0 | 6.2 ± 6.3 | 0.93 | 1.00 | 0.96–1.04 | 0.99 |
| CHA2DS2-VASc | 1.7 ± 1.5 | 2.0 ± 1.6 | 0.26 | 0.98 | 0.84–1.14 | 0.78 |
| Comorbidity | ||||||
| Hypertension, n(%) | 35(46) | 39(57) | 0.12 | 1.31 | 0.81–2.13 | 0.28 |
| Diabetes, n(%) | 7(9) | 8(12) | 0.41 | 1.05 | 0.46–2.07 | 0.90 |
| Coronary artery disease, n(%) | 10(13) | 12(18) | 0.30 | 1.52 | 0.77–2.75 | 0.21 |
| Heart failure, n(%) | 9(12) | 10(15) | 0.40 | 1.01 | 0.48–1.88 | 0.98 |
| Stroke/TIA, n(%) | 9(12) | 7(10) | 0.49 | 0.68 | 0.28–1.40 | 0.32 |
| Medication | ||||||
| AAD Class I or III, n (%) | 37(59) | 33(49) | 0.56 | 1.03 | 0.64–1.66 | 0.91 |
| β-blocker or CCB, n(%) | 50(66) | 45(66) | 0.55 | 1.43 | 0.87–2.41 | 0.16 |
| Essential Echo parameters | ||||||
| LAVI, mL/m2 | 39 ± 10 | 40 ± 11 | 0.41 | 1.00 | 0.98–1.03 | 0.55 |
| LVEDD, mm | 51 ± 5 | 50 ± 5 | 0.75 | 1.01 | 0.96–1.07 | 0.61 |
| LVESD, mm | 33 ± 5 | 33 ± 5 | 0.69 | 1.00 | 0.95–1.05 | 0.96 |
| LVEF, % | 61 ± 8 | 61 ± 7 | 0.91 | 1.00 | 0.98–1.04 | 0.63 |
| E/A ratio | 1.21 ± 0.52 | 1.53 ± 0.75 | 0.03 | 1.39 | 0.91–2.05 | 0.13 |
| RVSP, mmHg | 29 ± 5 | 29 ± 6 | 0.66 | 1.03 | 0.98–1.08 | 0.27 |
Values are mean ± SD or number (%)
CI confidence interval, HR hazard ratio; other abbreviations as in Table 1